KP1019 vs. KP1339 in Vietnam: An economical, chemical, and biological standpoint
DOI:
https://doi.org/10.47611/jsrhs.v13i3.7161Keywords:
KP1339, KP1019, Vietnam, ChemotherapyAbstract
This literature review introduces and compares two similar ruthenium-based anti-cancer metallodrugs, KP1019 and KP133, based on the factors of costs, induction stability, cytotoxicity, and overall effectiveness. Having a higher purity and scalability through Bold Therapeutics, KP1339 has emerged as the more promising chemotherapy for commercial use. In terms of induction, while KP1339 showed higher solubility, both drugs showed little to no statistical difference in the binding of human serum albumin and transferrin. However, unique induction sites were seen within cells, with KP1019 having a slightly higher toxicity and drug uptake.
Nonetheless, KP1339 is highlighted as the preferred chemotherapy due to its higher solubility, scalability, and promising clinical efficiency. Despite both drugs being in early clinical phases, KP1339's superior properties in solubility and commercial potential make it more suitable for widespread use, especially in countries with limited healthcare resources like Vietnam. In the end, continued research and developments are essential to fully unlock the therapeutic potential of ruthenium-based chemotherapies and address global cancer treatment needs.
Downloads
References or Bibliography
World Health Organization. (n.d.). Cancer. World Health Organization. https://www.who.int/vietnam/health-topics/cancer#:~:text=Cancer%20in%20Viet%20Nam&text=Viet%20Nam%20has%20aout%20165,100000%20population)%20rank%2057%20globally
a. General Statistics Office of Vietnam. (n.d.). Báo Cáo Tình Hình Kinh Tế - Xã Hội Quý IV và Năm 2022. https://www.gso.gov.vn/du-lieu-va-so-lieu-thong-ke/2022/12/bao-cao-tinh-hinh-kinh-te-xa-hoi-quy-iv-va-nam-2022/
GDP per capita (current US$). World Bank Open Data. (n.d.). https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?end=2022&most_recent_value_desc=false&start=1960&view=map&year=2018
Van Thuan T, Tuan Anh P, Van Tu D, Thi Thanh Huong T. Cancer control in Vietnam: where are we? | Cancer control. Cancel Control. 2016. http://www.cancercontrol.info/cc2016/cancer-control-in-vietnam-where-we-are/
a. Van Dyk, Jake, and Jerry J. Battista. "Cobalt-60: An old modality, a renewed challenge." Curr Oncol 3.10 (1996).
b. Centers for Disease Control and Prevention. (2018, April 4). CDC radiation emergencies. Centers for Disease Control andPrevention.https://www.cdc.gov/nceh/radiation/emergencies/isotopes/cobalt.htm#:~:text=Because%20it%20decays%20by%20gamma,acute%20radiation%20sickness%2C%20or%20death.
QuintilesIMS Institute. Global Oncology Trends 2017. https://www.communityoncology.org/wp-content/uploads/2017/06/QIIHI_Oncology_Trend_Report_2017_Advances_Complexity_Cost.pdf
Eisenstein, Ronald I., and David S. Resnick. "Going for the big one." Nature biotechnology 19.9 (2001): 881-882.
Stathopoulos, P. G.; Rigatos, S.; Stathopoulos, J.; Batzios, S. J.Drug Delivery Ther. 2012, 2, 106.
Scinto, Samuel L., et al. "Bioorthogonal chemistry." Nature Reviews Methods Primers 1.1 (2021): 30.
Wang, Dong, and Stephen J. Lippard. "Cellular processing of platinum anticancer drugs." Nature reviews Drug discovery 4.4 (2005): 307
El‐khateeb, Mahmoud, et al. "Development of HPLC conditions for valid determination of hydrolysis products of cisplatin." Journal of pharmaceutical sciences 88.3 (1999): 319-326.
P Schluga, Petra, et al. "Redox behavior of tumor-inhibiting ruthenium (III) complexes and effects of physiological reductants on their binding to GMP." Dalton transactions 14 (2006): 1796-1802.
Vaughan, G. T., and T. M. Florence. "Platinum in the human diet, blood, hair and excreta." Science of the total environment 111.1 (1992): 47-58.
Page, Simon M., Sally R. Boss, and Paul D. Barker. "Tuning heavy metal compounds for anti-tumor activity: is diversity the key to ruthenium’s success?" Future medicinal chemistry 1.3 (2009): 541-559.
Pieper, Thomas, Karl Borsky, and Bernhard K. Keppler. "Non-platinum antitumor compounds." Metallopharmaceuticals I: DNA Interactions (1999): 183-185.
Clinical trial number NCT04421820 for "BOLD-100 in combination with FOLFOX for the treatment of advanced solid tumours." at ClinicalTrials.gov
Antonarakis, Emmanuel S., and Ashkan Emadi. "Ruthenium-based chemotherapeutics: are they ready for prime time?." Cancer chemotherapy and pharmacology 66 (2010): 1-9.
History & IP. Bold Therapeutics | History & IP. (n.d.). https://www.bold-therapeutics.com/ip
MetalDaily.com: Live PGM Prices. Metals Daily. (n.d.). https://www.metalsdaily.com/live-prices/pgms/
The Facts on Arsenic. Dartmouth Toxic Metals Superfund Research Program. (n.d.). https://sites.dartmouth.edu/toxmetal/arsenic/the-facts-on-arsenic/#:~:text=Naturally%20occurring%20in%20the%20Earth%27s,the%2020th%20most%20abundant%20element.&text=In%20nature%20arsenic%20is%20usually,other%20elements%2C%20such%20as%20oxygen.
Bergamo, Alberta, and Gianni Sava. "Ruthenium complexes can target determinants of tumour malignancy." Dalton Transactions13 (2007): 1267-1272.
Stevens, Shannon K., et al. "The anticancer ruthenium complex KP1019 induces DNA damage, leading to cell cycle delay and cell death in Saccharomyces cerevisiae." Molecular pharmacology 83.1 (2013): 225-234.
Technology. Bold Therapeutics | Technology. (n.d.). https://www.bold-therapeutics.com/technology
Stearns, Lisa J., et al. "Assessment of health care utilization and cost of targeted drug delivery and conventional medical management vs conventional medical management alone for patients with cancer-related pain." JAMA Network Open 2.4 (2019): e191549-e191549.
P.F. Dimond, Gen. Eng. News 25 (2005) 21.
Lentz, Frederike, et al. "Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study." Anti-cancer drugs 20.2 (2009): 97-103.
Peti, Wolfgang, et al. "Synthesis of Tumor‐Inhibiting Complex Salts Containing the Anion trans‐Tetrachlorobis (indazole) ruthenate (III) and Crystal Structure of the Tetraphenylphosphonium Salt." European journal of inorganic chemistry 1999.9 (1999): 1551-1555.
Timerbaev, Andrei R., et al. "Comparative binding of antitumor indazolium [trans-tetrachlorobis (1H-indazole) ruthenate (III)] to serum transport proteins assayed by capillary zone electrophoresis." Analytical biochemistry 341.2 (2005): 326-333.
Połeć-Pawlak, Kasia, et al. "Application of capillary electrophoresis–inductively coupled plasma mass spectrometry to comparative studying of the reactivity of antitumor ruthenium (III) complexes differing in the nature of counter-ion toward human serum proteins." Journal of Chromatography A 1192.2 (2008): 323-326.
Trynda-Lemiesz, Lilianna, et al. "Studies on the interactions between human serum albumin and trans-indazolium (bisindazole) tetrachlororuthenate (III)." Journal of inorganic biochemistry 78.4 (2000): 341-346.
Dömötör, Orsolya, et al. "Characterization of the binding sites of the anticancer ruthenium (III) complexes KP1019 and KP1339 on human serum albumin via competition studies." JBIC Journal of Biological Inorganic Chemistry 18 (2013): 9-17.
Heffeter, Petra, et al. "Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339." JBIC Journal of Biological Inorganic Chemistry 15 (2010): 737-748.
Pizarro, Ana M., and Peter J. Sadler. "Unusual DNA binding modes for metal anticancer complexes." Biochimie 91.10 (2009): 1198-1211.
Galanski, M., et al. "Recent developments in the field of tumor-inhibiting metal complexes." Current Pharmaceutical Design 9.25 (2003): 2078-2089.
Allardyce, Claire S., and Paul J. Dyson. "Ruthenium in medicine: current clinical uses and future prospects." Platinum Metals Review 45.2 (2001): 62-69.
Hartinger, Christian G., et al. "From bench to bedside–preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis (1H-indazole) ruthenate (III)](KP1019 or FFC14A)." Journal of inorganic biochemistry 100.5-6 (2006): 891-904.
a. Keppler, B. K., et al. "New ruthenium complexes for the treatment of cancer." Ruthenium and Other Non-Platinum Metal Complexes in Cancer Chemotherapy. Springer Berlin Heidelberg, 1989.
b. Kapitza, S., et al. "Heterocyclic complexes of ruthenium (III) induce apoptosis in colorectal carcinoma cells." Journal of cancer research and clinical oncology 131 (2005): 101-110.
Aykul, Senem, and Erik Martinez-Hackert. "Determination of half-maximal inhibitory concentration using biosensor-based protein interaction analysis." Analytical biochemistry 508 (2016): 97-103.
Hartinger, Christian G., et al. "KP1019, a new redox‐active anticancer agent–Preclinical development and results of a clinical phase I study in tumor patients." Chemistry & biodiversity5.10 (2008): 2140-2155.
Wernitznig, Debora, et al. "First-in-class ruthenium anticancer drug (KP1339/IT-139) induces an immunogenic cell death signature in colorectal spheroids in vitro." Metallomics 11.6 (2019): 1044-1048.
Published
How to Cite
Issue
Section
Copyright (c) 2024 Trung Nhan Do
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
